ePrivacy and GPDR Cookie Consent by Cookie Consent

BLADDER CANCER: Durvalumab Plus Olaparib Combo Shows 50% Pathologic Complete Response in MIBC


Feb. 24, 2020


Neoadjuvant PD-L1 plus PARP inhibition (durvalumab + olaparib) delivered 50% complete pathologic response in a small (n=29) study of resectable muscle invasive disease. Biomarker studies to follow (ASCO GU 2020).

The combination of durvalumab (Imfinzi) and olaparib (Lynparza) may have activity as neoadjuvant therapy in the treatment of muscle-invasive bladder carcinoma (MIBC). In a single-arm phase II study (NCT03534492), the pathologic complete response rate (pCR) with the combination was 50%,1 reported Juan Francisco Rodriguez-Moreno, MD, at the 2020 Genitourinary Cancers Symposium...